Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1
Tests PACAB-002 in adults with ovarian cancer that has spread in the abdomen
Tests PACAB-002 for safety and dosing in adults with ovarian cancer spread to the abdomen.
Key facts
- Who runs it
- Nadeno Nanoscience AS
- Where
- Rotterdam, NetherlandsSee the site
- Trial code
- Registry title
- An open-label phase 1 dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and exploratory assessments of PACAB-002 in patients with ovarian cancer with peritoneal spread
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 21 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with ovarian cancer that has spread within the abdomen (peritoneal spread). It tests the safety of PACAB-002 at rising doses.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Ovarian cancer with peritoneal spread
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests PACAB-002 in adults with ovarian cancer that has spread in the abdomenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 October 2026